Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo chewses smoking cessation

This article was originally published in The Tan Sheet

Executive Summary

Perrigo receives ANDA generic drug approvals for over-the-counter nicotine polacrilex gum in 2mg and 4 mg doses Sept. 16. The approvals total six, with regular, mint and orange flavors for each dose. The approvals build on the firm's existing smoking cessation portfolio of nicotine replacement patch products (1"The Tan Sheet" Nov. 15, 1999, p. 13)....

You may also be interested in...

Watson Expects To Hold Nicotine Gum Market Position Despite Perrigo Entry

Watson does not expect an ongoing sales lag as a result of Perrigo's recent entry into the generic nicotine gum market

Perrigo Nicotine Patch Introduction Boosts First Quarter Sales Growth

The introduction of Perrigo's private label nicotine transdermal system helped the firm post strong sales and earnings growth for the first quarter ended Oct. 2, the company announced Nov. 9.

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts